Leucid Bio Chief Scientific Officer John Maher Publishes New Research on pCAR Technology
New data highlight the strength and versatility of Leucid’s proprietary, next-generation technology pCAR has now achieved proof-of-concept across a range of co-stimulatory domains, binders, targets